Monte Rosa Therapeutics Inc
Monte Rosa Therapeutics Inc (GLUE) Covered Calls
Monte Rosa Therapeutics Inc trades in the Biotechnology industry with an IV Rank of 1.59%, low versus the past year. GLUE's highest covered call setup is the $10.00 strike expiring Nov 20, 2026, sorted by theoretical annualized return. It's 6.72% out of the money with 7 days to expiration, a 8.32% return until expiration, and a 434.06% theoretical annualized return. Across the setups shown, annualized returns run from 39.97% to 434.06% at strikes between $10.00 and $15.00, with 7 to 154 days to expiration, as of Nov 13, 2026.
Read more
Running GLUE covered calls helps you generate income from Monte Rosa Therapeutics Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best GLUE covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If GLUE stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling GLUE covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given GLUE covered call is worth writing.
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies.
| 2026-11-20 | 7 | 10.00 | 6.72 | 0.15 | 0.40 | 78.00 | 8.32 | 434.06 | -1.60 | +0.34 | 2,998 | 0.25 |
| 2026-12-18 | 35 | 12.50 | 33.40 | 0.05 | 1.75 | 318.00 | 33.94 | 353.93 | -0.53 | +0.37 | 84 | 1.70 |
| 2027-04-16 | 154 | 15.00 | 60.09 | 1.05 | 4.90 | 668.00 | 71.29 | 168.97 | -11.21 | +0.58 | 1,197 | 3.85 |
| 2026-12-18 | 35 | 10.00 | 6.72 | 0.25 | 1.40 | 88.00 | 9.39 | 97.94 | -2.67 | +0.47 | 48 | 1.15 |
| 2027-04-16 | 154 | 10.00 | 6.72 | 0.95 | 4.80 | 158.00 | 16.86 | 39.97 | -10.14 | +0.64 | 299 | 3.85 |
As of Nov 13, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV Rank1.59% Low
- Market cap (M$)775
- 52 weeks high-64.80%
- 52 weeks low2.72%
- Analyst recommendationStrong Buy
1.00 - Target price$25.38
179.82% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-05
- P/E—
- Future P/E—
- EPS (ttm)-1.55
- EPS growth next 5 years—
As of Nov 17, 2026